Clinical trials: Neurological Observations
Acquired Brain Injury, Stroke
Computerized Attention Training for Individuals With Acquired Brain Injury
Problems with attention are a common and debilitating consequence of brain injury. Studies show that poor attention is the number one predictor of poor cognitive functioning one year post-injury.
- Conditions
- Acquired Brain Injury, Stroke, Hemispatial Neglect
- Trial name
- NCT01641432
- Testing
- Tonic and Phasic Attention Training, Active Comparator
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Posit Science Corporation
Friedreich Ataxia
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
- Trial name
- NCT05485987
- Testing
- Vatiquinone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- PTC Therapeutics
Parkinson Disease
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
This is an open-label, prospective post marketing surveillance study to be performed in Sweden. Only data of patients idiopathic PD should be documented, in whom the treating physician plans to initiate a pharmacotherapy with PPX…
- Trial name
- NCT01097421
- Testing
- Pramipexole Extended Release
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Back Pain, Low Back Pain
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
This was a clinical effectiveness trial designed to compare the effectiveness, safety, and tolerability of treatment with tapentadol prolonged release with that of oxycodone/naloxone prolonged release in non-opioid pre-treated…
- Conditions
- Back Pain, Low Back Pain, Neuropathic Pain
- Trial name
- NCT01838616
- Testing
- Tapentadol Prolonged Release, Oxycodone/Naloxone Prolonged Release
- Where
- 50 sites in Austria, Germany and 2 more
- Volunteers
- 367 people
- Sponsor
- Grünenthal GmbH
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Amyotrophic Lateral Sclerosis
To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts. After single dose administration, followed by an independent Data and Safety Monitoring Board (DSMB) meeting…
- Trial name
- NCT03651349
- Testing
- HK-001
- Where
- Taiwan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Everfront Biotech Co., Ltd.
Acute Stroke
Efficacy of EMF BCI Based Device on Acute Stroke
The study tests the efficacy of a non-invasive device with low intensity electromagnetic field dedicated treatment to enhance the recovery of stroke patients impaired hand motor function
- Trial name
- NCT04039178
- Testing
- BQ
- Where
- India
- Volunteers
- 28 people
- Sponsor
- BrainQ Technologies Ltd.
Fibromyalgia
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS). This trial consists of two distinct study periods.
- Trial name
- NCT01237587
- Testing
- Duloxetine
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 184 people
- Sponsor
- Eli Lilly and Company
Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3
- Trial name
- NCT02960893
- Testing
- Troriluzole
- Where
- 18 sites in United States
- Volunteers
- 141 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Carpal Tunnel Syndrome
Carpal Tunnel Release Using Ultrasound
The goal of the Carpal Tunnel Release Using Ultrasound registry (CiTRUS Registry) is to collect experience information from patients scheduled to undergo carpal tunnel release surgery with either the SX-One MicroKnife® with…
- Trial name
- CiTRUS (NCT05031338)
- Testing
- Carpal Tunnel Release
- Where
- United States
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- Sonex Health, Inc.
Tetraplegia/Tetraparesis, Quadriplegia
CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia).
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- CAN-PRIME (NCT06700304)
- Testing
- N1 Implant, R1 Robot
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Neuralink Corp
Brain Metastases
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
- Trial name
- NCT00538343
- Testing
- berubicin hydrochloride (RTA 744)
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Biogen
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Memory Loss
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
- Trial name
- NCT00293176
- Testing
- Donepezil Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 821 people
- Sponsor
- Eisai Inc.
Insomnia, Secondary, Sleep Disturbance
Robustness and Usability of the Dreem 3 System for at Home Sleep Monitoring in an Insomnia Population.
There is an unmet medical need for monitoring sleep for multiple nights in a patient's home, without the inconvenience of traveling and staying overnight in a medical center, and without the need for a technician to set up a…
- Conditions
- Insomnia, Secondary, Sleep Disturbance, Sleep, Sleep Initiation and Maintenance Disorders
- Trial name
- NCT05611099
- Testing
- Dreem 3 System vs WatchPAT One, Usability Questionnaire
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Dreem
Obstructive Sleep Apnea (OSA)
Foam Mask - Assessment of Bioburden in a New Mask Seal Material
Obstructive sleep apnoea (OSA) is characterised by a partial or complete collapse of the upper airway during sleep. The treatment of choice for OSA is Continuous Positive Airway Pressure (CPAP).
- Trial name
- NCT00773721
- Testing
- CPAP mask
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- ResMed
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer
FSHD, FSHD1
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
- Conditions
- FSHD, FSHD1, FSHD2, FMD
- Trial name
- FORTITUDE-OLE (NCT06547216)
- Testing
- AOC 1020
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 84 people
- Sponsor
- Avidity Biosciences, Inc.
Cerebral Palsy (CP), Spastic Paraplegia
Retrospective Study on the WalkOn AFO in Children or Teenagers With Neurological Pathologies
The goal of this observational study is to assess the interest of prefabricated carbon fiber ankle foot orthoses (AFO) in children and teenagers with central or peripheral neurological pathologies.
- Conditions
- Cerebral Palsy (CP), Spastic Paraplegia, Spinal Cord Injuries (SCI), Spina Bifida
- Trial name
- NCT06740006
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Otto Bock France SNC
Stroke
Myomo e100 NeuroRobotic System Home Safety Study
Up to 25 subjects will use the Myomoe100 in the home setting under the distant supervision of an occupational therapist. We will look to see if they can perform functional activities safely without adverse events.
- Trial name
- NCT00820638
- Testing
- myomo e100
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Myomo